Furthermore, FDG-PET has been used to distinguish between tumours, which are sensitive or resistant to mTOR inhibitors in various preclinical cancer models (McSheehy et al, 2005; Wei et al, 2008). This evidence concerns the gene MTOR and neoplasm.